Biotech Values

[DewDiligence]

GILD—Would it be enough for GS7340 [+Emtriva] to show better tolerability than Truvada or would it have to show better efficacy?

The former, IMO; I don’t think better efficacy than Truvada is a realistic goal for any dual-nuke backbone.

Another possible threat to Gilead is if nuke-sparing regimens eventually become popular.

Possible, yes, but this is less worrisome to GILD investors, IMO, than the 2017 loss of patent protection on Viread.